Researchers utilizing Tamarind Bio's no-code platform can now submit digital sequences directly into GenScript’s synthesis and testing infrastructure. By automating the handoff between computational design and physical verification, the partnership aims to cut the time required to generate model-ready experimental data to as little as four days. This integration allows teams to iterate on molecular candidates more rapidly, turning theoretical AI models into actionable biological evidence.

Ray Chen, President of GenScript Life Science Group, noted that while AI expands the horizons of what researchers can imagine, biology dictates the actual success of a drug program. By folding high-throughput lab validation into the early stages of discovery, the companies intend to resolve the capacity bottlenecks currently facing many research pipelines. For Tamarind Bio CEO Deniz Kavi, the collaboration fulfills a core mission to make sophisticated computational tools accessible, allowing scientists to move from digital concepts to physical results without the friction of manual logistics.